Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Quarterly profits miss forecasts at BP

(Sharecast News) - BP reported lower-than-expected quarterly income on Tuesday, as the energy major continued to overhaul its long-term strategy amid tumbling oil prices. The blue chip said underlying replacement cost profits - its core measure of income - were $1.38bn in the first quarter of 2025.

That was an improvement on the previous three months' $1.17bn, but down sharply on the $2.72bn posted in the first quarter of 2024. It was also below analyst forecasts for $1.53bn.

Net debt, meanwhile, jumped to $26.97bn from $24.02bn a year previously.

A $750m share buyback was announced, down on the $1.75bn announced in the fourth quarter

Under previous chief executive Bernard Looney, BP committed to move away from oil and gas and focus instead on renewables.

However, the share price has struggled since then, and current head Murray Auchincloss - who was appointed in September 2023 - has now committed to reverse the strategy and refocus on oil and gas.

The company has been further impacted this year by heightened market volatility and sliding oil prices, in response to Donald Trump's tariff regime and Opec-mandated supply hikes.

Auchincloss said: "In February, we announced a fundamental reset of our strategy - to grow the upstream, focus the downstream and invest with discipline - and we have already made significant progress.

"We continue to monitor market volatility and changes, and remain focused on moving at pace. I'm confident that our plans to strengthen the balance sheet, reduce costs and improve cash flow and returns will grow long-term shareholder value and strengthen the resilience of BP."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.